scout
|Videos|July 18, 2018

Efficacy of Nivolumab in Patients With Melanoma

Paolo A. Ascierto, MD, National Tumour Institute “Fondazione G. Pascale,” Unit of Melanoma in Naples, Italy, discusses the promising results for nivolumab (Opdivo) in patients with melanoma. 

Paolo A. Ascierto, MD, National Tumour Institute “Fondazione G. Pascale,” Unit of Melanoma in Naples, Italy, discusses the promising results for nivolumab (Opdivo) in patients with melanoma.

According to Ascierto, this agent has proven to be safe and efficacious in this patient population. The incidence of grade 3/4 adverse events (AEs) is also low.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME